StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Kyverna Therapeutics's total debt was $24.96M at Sep 30, 2026. For fiscal 2025 it was $24.74M.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$24.74M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$24.96M–
Q2 FY2026Jun 30, 2026$24.88M–
Q4 FY2025Dec 31, 2025$24.74M–

More Kyverna Therapeutics figures

See a number that looks wrong?